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data to estimate the value of a drug for an indication. We
assessed analyses’ compliance with several criteria recommended
by the Panel on Cost-Effectiveness in Health and Medicine.
RESULTS: Of 115 dossiers submitted, 55% included economic
analyses. We found 106 analyses supporting economic claims for
drugs on speciﬁc indications. Of these, 89% adopted a payer per-
spective, 48% were cost minimization analyses, 58% had time
horizons < 2 years. 14% applied discounting; 20% stated all
assumptions clearly; 37% compared relevant alternatives; 21%
reported resource quantities separately, 13% productivity losses,
and 26% incremental results; 42% performed some form of sen-
sitivity analysis; 18% mentioned caveats to conclusions. Analy-
ses of high-cost products were more likely to be cost effectiveness
or cost consequence analyses (OR = 12.5, p = 0.004) and to
compare relevant alternatives (OR = 6.4, p = 0.008). Analyses of
me-too drugs were less likely to state all assumptions clearly 
(OR = 0.23, p = 0.016), compare relevant alternatives (OR =
0.09, p = 0.0001), report sensitivity analyses (OR = 0.19, 
p = 0.006) or incremental results (OR = 0.28, p = 0.03). No 
other signiﬁcant differences found. CONCLUSIONS: Most 
AMCP-Format dossier submissions included economic analyses,
but these had low levels of compliance with accepted recom-
mendations. Analyses of me-too drugs appeared particularly
prone to bias.
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OBJECTIVES: Conventional typical-antipsychotics are less tol-
erated than newer atypical-antipsychotics. Concerns about using
antipsychotic-combinations also exist. However, national studies
of antipsychotic use at United States (US) ambulatory visits are
limited. The study objectives were to determine national esti-
mates and associated factors of antipsychotic (typical, atypical,
and combination) use. METHODS: Retrospective analyses were
conducted of the combined 8-year data (1996–2003) of ofﬁce-
based National Ambulatory Medical Care Survey (NAMCS) and
outpatient National Hospital Ambulatory Medical Care Survey
(NHAMCS). Mental-health disorder visits with ICD-9-CM 
diagnostic-codes (290–319, 331.0x) were classiﬁed into three
mutually exclusive visit-groups: typical, atypical or combined-
antipsychotic. Sample estimates were weighted and projected to
the population with 95% conﬁdence intervals. Multivariable
logistic regression was used to determine signiﬁcant factors asso-
ciated with typical- versus atypical-antipsychotic mention at
visits. RESULTS: About 47.7million visits or 0.83%
(95%CI:0.73–0.93) of all adult visits had a mental-health disor-
der and an antipsychotic mention: atypical (30 million visits),
typical (15.3 million visits), and combination (2.4 million visits).
Major antipsychotics across visit-groups were: typical (haloperi-
dol, thioridazine, ﬂuphenazine); atypical (risperidone, olanzap-
ine, quiteapine); and combination (haloperidol, risperidone,
olanzapine). Compared with typical-, the likelihood of atypical-
antipsychotic visits increased over time. More typical- and 
combination- versus atypical-antipsychotic visits (30% and 
37% vs. 7%) included medications to treat extrapyramidal side
effects (EPS). In multivariable logistic-regression analysis, con-
trolling for gender, schizophrenia-diagnosis, and behavioral-
treatment; age greater than 40 versus 18–40 years (odds-ratio,
OR, 0.65, 95%CI:0.49–0.85) and nonprivate insurance 
reimbursement-sources signiﬁcantly decreased while comorbid
depression (OR, 1.9, 95%CI:1.23–2.85), and bipolar-disorder
(OR, 2.0, 95%CI:1.27–3.24), signiﬁcantly increased the likeli-
hood of atypical- relative to typical-antipsychotic mention at
visits (p < 0.05). CONCLUSIONS: Although combination-
antipsychotic visits were low, 37% of these visits included med-
ications to treat EPS. Atypical-antipsychotic use was more likely
at visits by younger patients, with comorbid diagnoses (depres-
sion, bipolar-disorder), and private insurance reimbursement-
source. This highlights important case-mix factors of
antipsychotic use warranting attention in US ambulatory care to
guide formulary-decisions.
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OBJECTIVES: To reﬁne and evaluate the validity and reliability
of the Hyperpigmentation Treatment Satisfaction Questionnaire
(HPTSQ). The HPTSQ was designed to measure medication
treatment satisfaction for subjects with hyperpigmentation,
either melasma (pregnancy mask) or solar lentigines (age spots).
METHODS: All analyses were conducted on data from a cross-
sectional sample of subjects who reported having hyperpigmen-
tation and completed the HPTSQ online. RESULTS: A total of
635 respondents (573 with solar lentigines and 62 with melasma)
completed the HPTSQ. Factor analysis, Item Response Theory
(IRT) and traditional psychometric analyses were used to select
the 26 items in ﬁve factors/ domains from an initial pool of 38
items. These ﬁve domains had the following properties: 1) Efﬁ-
cacy—7 items, á coefﬁcient 0.96; 2) Side Effects—5 items, á coef-
ﬁcient 0.95; 3) Physical Properties—5 items, á coefﬁcient 0.88;
4) Convenience—5 items, á coefﬁcient 0.87; and 5) Overall Sat-
isfaction—4 items, á coefﬁcient 0.93. Domains 1, 3, 4, and 5
showed strong test-retest reliability (intra-class correlations
0.77–0.87), while Domain 2 had an ICC of 0.44 (0.52 for sub-
jects reporting side effects at both baseline and follow-up). All
domains of the HPTSQ showed strong construct validity when
correlated with related domains on three comparable patient-
reported instruments. Based on level of treatment satisfaction,
all domains of the HPTSQ showed strong known-groups valid-
ity (p < 0.01), except Domain 2 (Side Effects). CONCLUSIONS:
The 26-item HPTSQ is a psychometrically sound and valid
measure of solar lentigines and melasma subjects’ treatment sat-
isfaction with medication. Responsiveness testing of the HPTSQ
should be conducted in a prospective clinical trial.
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OBJECTIVE: To determine the validity and sensitivity to change
of the Work Productivity Questionnaire (WPQ) in a large,
national sample of participants in the Multicenter Assessment of
Transdermal Therapy in Overactive Bladder with Oxybutynin
(MATRIX). METHODS: The WPQ is an 8-item subset of the
Work Limitations Questionnaire (WLQ) which measures the
